source
- Bausch + Lomb moves dry-eye eye drop to Phase 3 despite missing primary endpoint in Phase 2Bausch + Lomb reported results of a Phase 2 trial of its dual-action dry-eye eye drop, which combines 5% lifitegrast (the active ingredient in Xiidra) with perfluorohexyloctane (PHFO, sold as Miebo…
- AI can flag drug theft in hospitals, but alerts need human follow-up, case showsIn September 2024, a travel nurse at Adventist Health in Bakersfield, California, was observed behaving erratically and was later found to be diverting opioids from a secured cabinet, documenting t…